[go: up one dir, main page]

MX2018006477A - Anticuerpos y metodos de uso de estos. - Google Patents

Anticuerpos y metodos de uso de estos.

Info

Publication number
MX2018006477A
MX2018006477A MX2018006477A MX2018006477A MX2018006477A MX 2018006477 A MX2018006477 A MX 2018006477A MX 2018006477 A MX2018006477 A MX 2018006477A MX 2018006477 A MX2018006477 A MX 2018006477A MX 2018006477 A MX2018006477 A MX 2018006477A
Authority
MX
Mexico
Prior art keywords
gitr
activity
human
antibodies
multispecific
Prior art date
Application number
MX2018006477A
Other languages
English (en)
Inventor
Leger Olivier
J Underwood Dennis
Schaer David
Ritter Gerd
Merghoub Taha
Seibert Volker
Hirschhorn-Cymerman Daniel
S Wilson Nicholas
Van Dijk Marc
D Waight Jeremy
V Breous-Nystrom Ekaterina
Tsuji Takemasa
Original Assignee
Agenus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agenus Inc filed Critical Agenus Inc
Publication of MX2018006477A publication Critical patent/MX2018006477A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente descripción proporciona anticuerpos multiespecíficos (por ejemplo, biespecíficos) que se unen especialmente a GITR humano y/o a OX40 humano así como también composiciones que comprenden tales anticuerpos. En un aspecto específico, los anticuerpos multiespecíficos se unen específicamente a GITR y a OX40 humanos y modulan la actividad de GITR y/o de OX40, por ejemplo, potencian, activan, o inducen la actividad de GITR y/o de OX40, o reducen, desactivan, o inhiben la actividad de GITR y/o de OX40. La presente descripción también proporciona métodos para tratar trastornos, tales como cáncer, mediante la administración de un anticuerpo multiespecífico que se une específicamente a GITR y/o OX40 humanos y modula la actividad de GITR y/o de OX40, por ejemplo, potencia, activa, o induce la actividad de GITR y/o de OX40. También se proporciona métodos para tratar enfermedades o trastornos autoimunitarios o inflamatorios, mediante la administración de un anticuerpo multiespecífico que se une específicamente a GITR y/o a OX40 humanos y modula la actividad de GITR y/o de OX40, por ejemplo, reduce, desactiva, o inhibe la actividad de GITR y/o de OX40.
MX2018006477A 2015-12-02 2016-12-02 Anticuerpos y metodos de uso de estos. MX2018006477A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562262369P 2015-12-02 2015-12-02
US201662419911P 2016-11-09 2016-11-09
PCT/US2016/064642 WO2017096179A1 (en) 2015-12-02 2016-12-02 Antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2018006477A true MX2018006477A (es) 2018-09-03

Family

ID=58797808

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018006477A MX2018006477A (es) 2015-12-02 2016-12-02 Anticuerpos y metodos de uso de estos.

Country Status (13)

Country Link
US (5) US11447557B2 (es)
EP (1) EP3383430A4 (es)
JP (3) JP7089470B2 (es)
KR (1) KR20180083944A (es)
CN (2) CN108883173B (es)
AU (1) AU2016364889B2 (es)
CA (1) CA3007233A1 (es)
IL (2) IL299072A (es)
MA (1) MA44312A (es)
MX (1) MX2018006477A (es)
SG (2) SG11201804265XA (es)
TW (2) TWI717432B (es)
WO (1) WO2017096179A1 (es)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201912986PA (en) 2014-05-28 2020-02-27 Agenus Inc Anti-gitr antibodies and methods of use thereof
CN115109158A (zh) 2015-05-07 2022-09-27 阿吉纳斯公司 抗ox40抗体及其使用方法
IL299072A (en) 2015-12-02 2023-02-01 Memorial Sloan Kettering Cancer Center Antibodies and methods of use thereof
US20200079862A1 (en) * 2015-12-03 2020-03-12 Agenus Inc. Anti-ox40 antibodies and methods of use thereof
WO2017100372A1 (en) 2015-12-07 2017-06-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and psma
WO2017218707A2 (en) 2016-06-14 2017-12-21 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
EP4342912A3 (en) 2016-09-23 2024-05-22 Merus N.V. Binding molecules that modulate a biological activity expressed by a cell
WO2018089628A1 (en) * 2016-11-09 2018-05-17 Agenus Inc. Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
JOP20190100A1 (ar) 2016-11-19 2019-05-01 Potenza Therapeutics Inc بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
WO2019028182A2 (en) * 2017-08-01 2019-02-07 Remd Biotherapeutics, Inc. TREATMENT OF CANCER USING ANTIBODIES BINDING TO THE HUMAN CD134 RECEPTOR (OX40)
JP2021501801A (ja) 2017-11-01 2021-01-21 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 癌の処置に用いるための免疫刺激アゴニスト抗体
CN108218990B (zh) * 2017-12-29 2021-03-02 南京优迈生物科技有限公司 分离的抗体或其抗原结合片段及其在肿瘤治疗中的应用
JP7351845B2 (ja) 2018-03-23 2023-09-27 ブリストル－マイヤーズ スクイブ カンパニー Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用
SG11202012043RA (en) 2018-07-03 2021-01-28 Gilead Sciences Inc Antibodies that target hiv gp120 and methods of use
US20210277135A1 (en) 2018-07-13 2021-09-09 Bristol-Myers Squibb Company Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a method of treating a cancer or a solid tumor
CN110872349A (zh) * 2018-09-04 2020-03-10 三生国健药业（上海）股份有限公司 结合人il-4r的抗体、其制备方法和用途
WO2020102647A1 (en) * 2018-11-15 2020-05-22 Invenra Inc. Multivalent receptor-clustering agonist antibody constructs and antigen binding proteins
CN111375059B (zh) * 2018-12-29 2024-04-16 江苏恒瑞医药股份有限公司 一种抗gitr抗体药物组合物及其用途
US10442866B1 (en) * 2019-01-23 2019-10-15 Beijing Mabworks Biotech Co. Ltd Antibodies binding OX40 and uses thereof
WO2020197991A1 (en) 2019-03-22 2020-10-01 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
CN111109198B (zh) * 2019-03-29 2021-08-20 成都华西海圻医药科技有限公司 一种葡萄膜炎动物模型构建方法
TWI762925B (zh) 2019-05-21 2022-05-01 美商基利科學股份有限公司 鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法
US20220363760A1 (en) 2019-05-30 2022-11-17 Bristol-Myers Squibb Company Multi-tumor gene signature for suitability to immuno-oncology therapy
WO2020243568A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
KR20220016157A (ko) 2019-05-30 2022-02-08 브리스톨-마이어스 스큅 컴퍼니 세포 국재화 시그너쳐 및 조합 요법
US20210009718A1 (en) 2019-06-25 2021-01-14 Gilead Sciences, Inc. FLT3L-Fc FUSION PROTEINS AND METHODS OF USE
KR20220047277A (ko) 2019-07-16 2022-04-15 길리애드 사이언시즈, 인코포레이티드 Hiv 백신, 및 이의 제조 및 사용 방법
US20220257619A1 (en) 2019-07-18 2022-08-18 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
US11497808B2 (en) 2019-09-30 2022-11-15 Gilead Sciences, Inc. HBV vaccines and methods treating HBV
PH12022550835A1 (en) 2019-10-18 2023-07-03 Forty Seven Inc Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
CN114599392A (zh) 2019-10-31 2022-06-07 四十七公司 基于抗cd47和抗cd20的血癌治疗
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
EP4567109A3 (en) 2019-12-06 2025-09-17 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
MX2022007930A (es) 2019-12-24 2022-08-08 Carna Biosciences Inc Compuestos moduladores de diacilglicerol quinasa.
MX2022009947A (es) 2020-02-14 2022-11-07 Jounce Therapeutics Inc Anticuerpos y proteinas de fusion que se unen a ccr8 y usos de estos.
TW202421168A (zh) 2020-03-20 2024-06-01 美商基利科學股份有限公司 4’-c-經取代-2-鹵基-2’-去氧腺苷核苷之前藥及其製造與使用方法
JP2023518835A (ja) * 2020-03-26 2023-05-08 エショー バイオセラピー， インク． 制御性ｔ細胞の除去用の二重特異性融合タンパク質
KR20230006891A (ko) 2020-05-01 2023-01-11 길리애드 사이언시즈, 인코포레이티드 Cd73를 억제하는 2,4-다이옥소피리미딘 화합물
EP4153181A1 (en) 2020-05-21 2023-03-29 Gilead Sciences, Inc. Pharmaceutical compositions comprising bictegravir
WO2022031894A1 (en) 2020-08-07 2022-02-10 Gilead Sciences, Inc. Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use
WO2022037662A1 (en) * 2020-08-21 2022-02-24 Wuxi Biologics (Shanghai) Co. Ltd. Cd40 agonistic antibody and method of use
CN112043696B (zh) * 2020-08-26 2023-02-24 深圳市第二人民医院(深圳市转化医学研究院) Ido-1抑制剂在制备治疗骨性关节炎药物中的应用
WO2022047412A1 (en) 2020-08-31 2022-03-03 Bristol-Myers Squibb Company Cell localization signature and immunotherapy
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
WO2022103758A1 (en) 2020-11-11 2022-05-19 Gilead Sciences, Inc. METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
WO2022146948A1 (en) 2020-12-28 2022-07-07 Bristol-Myers Squibb Company Subcutaneous administration of pd1/pd-l1 antibodies
US20220233693A1 (en) 2020-12-28 2022-07-28 Bristol-Myers Squibb Company Antibody Compositions and Methods of Use Thereof
MX2023007901A (es) 2020-12-31 2023-07-11 Sanofi Sa Acopladores de celulas asesinas naturales (nk) multifuncionales que se unen a nkp46 y a cd123.
TW202246334A (zh) 2021-02-02 2022-12-01 美商美國禮來大藥廠 Gitr拮抗劑及其使用方法
US20240376224A1 (en) 2021-04-02 2024-11-14 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
EP4337223A1 (en) 2021-05-13 2024-03-20 Gilead Sciences, Inc. Combination of a tlr8 modulating compound and anti-hbv sirna therapeutics
TW202313094A (zh) 2021-05-18 2023-04-01 美商基利科學股份有限公司 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
EP4359413A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
US11976072B2 (en) 2021-06-23 2024-05-07 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
MX2023014762A (es) 2021-06-23 2024-01-15 Gilead Sciences Inc Compuestos moduladores de diacilglicerol quinasa.
EP4359411A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
JP2024539252A (ja) 2021-10-28 2024-10-28 ギリアード サイエンシーズ， インコーポレイテッド ピリジジン－３（２ｈ）－オン誘導体
JP7787991B2 (ja) 2021-10-29 2025-12-17 ギリアード サイエンシーズ， インコーポレイテッド Ｃｄ７３化合物
JP7765637B2 (ja) 2021-12-03 2025-11-06 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖウイルス感染症のための治療化合物
CN118369316A (zh) 2021-12-03 2024-07-19 吉利德科学公司 Hiv病毒感染的治疗性化合物
CA3235937A1 (en) 2021-12-03 2023-06-08 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
WO2023107956A1 (en) 2021-12-08 2023-06-15 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and 5t4
WO2023107954A1 (en) 2021-12-08 2023-06-15 Dragonfly Therapeutics, Inc. Antibodies targeting 5t4 and uses thereof
EP4452415A1 (en) 2021-12-22 2024-10-30 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CN118488946A (zh) 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
HUE069263T2 (hu) 2022-03-17 2025-02-28 Gilead Sciences Inc Ikarosz cink-ujj család degradálói és azok alkalmazása
JP2025509749A (ja) 2022-03-18 2025-04-11 ブリストル－マイヤーズ スクイブ カンパニー ポリペプチドの単離方法
JP2025509662A (ja) 2022-03-24 2025-04-11 ギリアード サイエンシーズ， インコーポレイテッド Ｔｒｏｐ－２発現がんを治療するための併用療法
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
TWI843506B (zh) 2022-04-06 2024-05-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
US20230374036A1 (en) 2022-04-21 2023-11-23 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2023215560A1 (en) 2022-05-05 2023-11-09 Atoosa Corporation Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp)
AU2023274452A1 (en) 2022-05-27 2025-01-16 Innate Pharma Natural killer (nk) cell engagers binding to nkp46 and bcma variants with fc-engineering
JP2025518785A (ja) 2022-06-02 2025-06-19 ブリストル－マイヤーズ スクイブ カンパニー 抗体組成物及びその使用方法
TW202434566A (zh) 2022-07-01 2024-09-01 美商基利科學股份有限公司 可用於hiv病毒感染之疾病預防性或治療性治療的治療性化合物
PE20250758A1 (es) 2022-07-01 2025-03-13 Gilead Sciences Inc Compuestos de cd73
EP4554628A1 (en) 2022-07-12 2025-05-21 Gilead Sciences, Inc. Hiv immunogenic polypeptides and vaccines and uses thereof
AU2023330037A1 (en) 2022-08-26 2025-03-06 Gilead Sciences, Inc. Dosing and scheduling regimen for broadly neutralizing antibodies
EP4583999A1 (en) 2022-09-09 2025-07-16 Bristol-Myers Squibb Company Methods of separating chelator
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
EP4598934A1 (en) 2022-10-04 2025-08-13 Gilead Sciences, Inc. 4'-thionucleoside analogues and their pharmaceutical use
KR20250122479A (ko) 2022-12-22 2025-08-13 길리애드 사이언시즈, 인코포레이티드 Prmt5 억제제 및 이의 용도
WO2024196952A1 (en) 2023-03-20 2024-09-26 Bristol-Myers Squibb Company Tumor subtype assessment for cancer therapy
US20240383922A1 (en) 2023-04-11 2024-11-21 Gilead Sciences, Inc. KRAS Modulating Compounds
AR132464A1 (es) 2023-04-19 2025-07-02 Gilead Sciences Inc Régimen de dosificación de inhibidor de la cápside
WO2024220917A1 (en) 2023-04-21 2024-10-24 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2024249592A1 (en) 2023-05-31 2024-12-05 Gilead Sciences, Inc. Quinazolinyl-indazole derivatives as therapeutic compounds for hiv
TW202504592A (zh) 2023-05-31 2025-02-01 美商基利科學股份有限公司 固體形式
US20250042922A1 (en) 2023-06-30 2025-02-06 Gilead Sciences, Inc. Kras modulating compounds
US12319747B2 (en) 2023-07-03 2025-06-03 Medicovestor, Inc. Methods of using anti-SP17 immunotherapeutics
WO2025024811A1 (en) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Parp7 inhibitors
US20250066328A1 (en) 2023-07-26 2025-02-27 Gilead Sciences, Inc. Parp7 inhibitors
WO2025029247A1 (en) 2023-07-28 2025-02-06 Gilead Sciences, Inc. Weekly regimen of lenacapavir for the treatment and prevention of hiv
WO2025038763A1 (en) 2023-08-15 2025-02-20 Bristol-Myers Squibb Company Ceramic hydroxyapatite chromatography flow through method
WO2025042394A1 (en) 2023-08-23 2025-02-27 Gilead Sciences, Inc. Dosing regimen of hiv capsid inhibitor
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025054347A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250122219A1 (en) 2023-10-11 2025-04-17 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
WO2025080850A1 (en) 2023-10-11 2025-04-17 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
TW202515549A (zh) 2023-10-11 2025-04-16 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
US12364777B2 (en) 2023-10-20 2025-07-22 Medicovestor, Inc. Homodimeric antibodies for use in treating cancers and methods of use
US20250154172A1 (en) 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025137245A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
US12116410B1 (en) 2023-12-26 2024-10-15 Medicovestor, Inc. Methods of manufacturing dimeric antibodies
US20250206847A1 (en) * 2023-12-26 2025-06-26 Medicovestor, Inc. Dimeric antibodies and their methods of manufacture
US20250215087A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg depleting agent
WO2025184447A1 (en) 2024-03-01 2025-09-04 Gilead Sciences, Inc. Pharmaceutical compositions comprising hiv integrase inhibitors
US20250289822A1 (en) 2024-03-01 2025-09-18 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
US20250333424A1 (en) 2024-03-01 2025-10-30 Gilead Sciences, Inc. Antiviral compounds
WO2025240242A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
US20250345389A1 (en) 2024-05-13 2025-11-13 Gilead Sciences, Inc. Combination therapies
WO2025240246A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
WO2025240244A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025260028A1 (en) 2024-06-14 2025-12-18 Gilead Sciences, Inc. Pharmaceutical compositions comprising hiv integrase inhibitors

Family Cites Families (278)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
WO1995001997A1 (en) 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
US5821332A (en) 1993-11-03 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor on the surface of activated CD4+ T-cells: ACT-4
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5997873A (en) 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5759546A (en) 1994-02-04 1998-06-02 Weinberg; Andrew D. Treatment of CD4 T-cell mediated conditions
US6242566B1 (en) 1994-02-10 2001-06-05 Board Of Trustees Of The Leland Stanford Junior University Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
USRE38313E1 (en) 1994-05-06 2003-11-11 Institut Gustave Roussy Soluble polypeptide fractions of the LAG-3 protein, production method, therapeutic composition, anti-idiotype antibodies
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
DK0843557T3 (da) 1995-07-21 2003-03-10 Inst Nat Sante Rech Med Fremgangsmåder til detektion, identifikation, isolation og selektiv mærkning og målsøgning af Th1-lymfocytter ved hjælp af LAG-3 protein
US5935576A (en) 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6017540A (en) 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
WO1998042752A1 (en) 1997-03-21 1998-10-01 Brigham And Women's Hospital Inc. Immunotherapeutic ctla-4 binding peptides
AU734180B2 (en) 1997-08-29 2001-06-07 Antigenics Llc Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient
US6503184B1 (en) 1997-10-21 2003-01-07 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
JP2001520039A (ja) 1997-10-21 2001-10-30 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ヒト腫瘍壊死因子レセプター様タンパク質、ｔｒ１１，ｔｒ１１ｓｖ１およびｔｒ１１ｓｖ２
US5948646A (en) 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
WO1999040196A1 (en) 1998-02-09 1999-08-12 Genentech, Inc. Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
CA2321161C (en) 1998-02-24 2011-12-20 Andrew D. Weinberg Compositions containing an ox-40 receptor binding agent or a nucleic acid encoding the same and methods for enhancing antigen-specific immune response
US6312700B1 (en) 1998-02-24 2001-11-06 Andrew D. Weinberg Method for enhancing an antigen specific immune response with OX-40L
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
AU773204C (en) 1998-08-10 2005-05-19 Antigenics Llc Compositions of CPG and saponin adjuvants and methods thereof
SG143018A1 (en) 1998-12-23 2008-06-27 Pfizer Human monoclonal antibodies to ctla-4
US20030035790A1 (en) 1999-01-15 2003-02-20 Shu-Hsia Chen Combination therapy for the prevention or treatment of cancer, inflammatory disorders or infectious diseases in a subject
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
ES2694002T3 (es) 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
WO2001014557A1 (en) 1999-08-23 2001-03-01 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
US7034121B2 (en) 2000-01-27 2006-04-25 Genetics Institue, Llc Antibodies against CTLA4
PT2857516T (pt) 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
WO2002028440A1 (en) 2000-10-02 2002-04-11 The Scripps Research Institute Methods and compositions for modulating t cell activation and uses thereof
ES2649037T3 (es) 2000-12-12 2018-01-09 Medimmune, Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US20150329617A1 (en) 2001-03-14 2015-11-19 Dynal Biotech Asa Novel MHC molecule constructs, and methods of employing these constructs for diagnosis and therapy, and uses of MHC molecules
IL149701A0 (en) 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies
WO2003006058A1 (en) 2001-07-12 2003-01-23 Wyeth Cd25+ differential markers and uses thereof
CA2466279A1 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
US20050123536A1 (en) 2001-11-20 2005-06-09 Che-Leung Law Treatment of immunological disorders using anti-dc30 antibodies
TW200303759A (en) 2001-11-27 2003-09-16 Schering Corp Methods for treating cancer
AU2002365814A1 (en) 2001-12-18 2003-07-30 J And J Research Pty Ltd Method of treating asthma
JP4694128B2 (ja) 2002-01-30 2011-06-08 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド ＴＩＭ−３、Ｔｈ１特異的細胞表面分子に関連した組成物および方法
AUPS054702A0 (en) 2002-02-14 2002-03-07 Immunaid Pty Ltd Cancer therapy
AU2003224810B2 (en) 2002-03-26 2006-08-31 Immunex Corporation Methods of using Flt3-ligand in immunization protocols
AR039209A1 (es) 2002-04-03 2005-02-09 Novartis Ag Derivados de indolilmaleimida
ATE552849T1 (de) 2002-04-12 2012-04-15 Medarex Inc Behandlungsverfahren unter verwendung von ctla-4 antikörpern
US20030223989A1 (en) * 2002-04-18 2003-12-04 Pluenneke John D. CD137 agonists to treat patients with IgE-mediated conditions
WO2003106498A2 (en) 2002-06-13 2003-12-24 Crucell Holland, B.V. Agonistic binding molecules to the human ox40 receptor
US7595048B2 (en) 2002-07-03 2009-09-29 Ono Pharmaceutical Co., Ltd. Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1
JP5068931B2 (ja) 2002-07-12 2012-11-07 ザ ジョンズ ホプキンス ユニバーシティー 独自のクローン形質のリンパ球受容体に結合する試薬および方法
US7291331B1 (en) 2002-09-11 2007-11-06 La Jolla Institute For Allergy And Immunology Methods of treating OX40 medicated recall immune responses
CA2503457A1 (en) 2002-10-25 2004-05-06 University Of Connecticut Health Center Apparatus and method for immunotherapy of a cancer through controlled cell lysis
DE10261223A1 (de) 2002-12-20 2004-07-08 MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH Steigerung der Immunantwort durch Substanzen, welche die Funktion von Natürlichen Killerzellen beeinflussen
BR0316880A (pt) 2002-12-23 2005-10-25 Wyeth Corp Anticorpos contra pd-1 e usos dos mesmos
EP2572715A1 (en) 2002-12-30 2013-03-27 3M Innovative Properties Company Immunostimulatory Combinations
GB0303319D0 (en) 2003-02-13 2003-03-19 Novartis Ag Organic compounds
GB0303663D0 (en) 2003-02-18 2003-03-19 Lorantis Ltd Assays and medical treatments
CA2517287C (en) 2003-02-28 2022-12-13 The Johns Hopkins University Regulation of t cells by lag-3 (cd223)
US20040197312A1 (en) 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
US7402431B2 (en) 2004-03-01 2008-07-22 Immunovative Therapies, Ltd. T-cell therapy formulation
US7435592B2 (en) 2003-05-13 2008-10-14 Immunovative Therapies, Ltd. Compositions for allogeneic cell therapy
US7618632B2 (en) 2003-05-23 2009-11-17 Wyeth Method of treating or ameliorating an immune cell associated pathology using GITR ligand antibodies
US7465446B2 (en) 2003-05-30 2008-12-16 Medarex, Inc. Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease
RU2005141512A (ru) 2003-05-31 2007-07-20 Микромет Аг (De) Фармацевтические композиции, включающие биспецифические анти-cd3, анти-cd19 конструкции антител для лечения расстройств, связанных с b-клетками
CA2529307C (en) 2003-06-13 2013-12-24 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1660126A1 (en) 2003-07-11 2006-05-31 Schering Corporation Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer
EP1670507A4 (en) 2003-09-12 2007-10-17 Antigenics Inc VACCINE FOR THE TREATMENT AND PREVENTION OF HERPES SIMPLEX VIRUS INFECTION
BRPI0415533A (pt) 2003-10-24 2006-12-26 Immunaid Pty Ltd método de terapia
WO2005049085A1 (en) 2003-11-18 2005-06-02 Valeocyte Therapies Llc Use of soluble complexes to facilitate cell activation
US7691861B2 (en) 2004-01-19 2010-04-06 Novartis Ag Indolymaleimide derivatives
US7592431B2 (en) 2004-02-26 2009-09-22 Immunovative Therapies, Ltd. Biodegradable T-cell Activation device
KR20060132006A (ko) 2004-03-23 2006-12-20 비오겐 아이덱 엠에이 아이엔씨. 수용체 커플링제 및 이의 치료적 용도
CA2560919A1 (en) 2004-03-26 2005-10-06 Pfizer Products Inc. Uses of anti-ctla-4 antibodies
BRPI0510716A (pt) 2004-05-05 2007-11-20 Merrimack Pharmaceuticals Inc uso de um agente de ligação bi-especìfico, agente de ligação bi-especìfico, composição de um agente de ligação bi-especìfico, e, kit
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
DE102004063494A1 (de) 2004-12-23 2006-07-13 Tegenero Ag Antikörper
CA2602777C (en) 2005-03-25 2018-12-11 Tolerrx, Inc. Gitr binding molecules and uses therefor
CA2606809C (en) 2005-05-06 2016-01-05 Providence Health System Trimeric ox40-immunoglobulin fusion protein and methods of use
EP2439273B1 (en) 2005-05-09 2019-02-27 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
JP2006345852A (ja) 2005-06-16 2006-12-28 Virxsys Corp 抗体複合体
GB0512225D0 (en) 2005-06-16 2005-07-27 Univ Sheffield Immunoglobulin molecules
CN104072614B (zh) * 2005-07-08 2017-04-26 生物基因Ma公司 抗-αvβ6 抗体及其用途
WO2007016340A2 (en) 2005-07-29 2007-02-08 Providence Health System Defective ribosomal products in blebs (dribbles) and methods of use to stimulate an immune response
EP1941275B1 (en) * 2005-09-29 2013-07-24 Medimmune, Inc. Method of identifying membrane lg specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells
US20110305713A1 (en) 2005-10-21 2011-12-15 Medical College Of Georgia Research Institute, Inc Methods and compositions to enhance vaccine efficacy by reprogramming regulatory t cells
TW200732350A (en) 2005-10-21 2007-09-01 Amgen Inc Methods for generating monovalent IgG
WO2007056539A2 (en) 2005-11-08 2007-05-18 Medarex, Inc. Prophylaxis and treatment of enterocolitis associated with anti-ctla-4 antibody therapy
WO2007060918A1 (ja) 2005-11-24 2007-05-31 Dainippon Sumitomo Pharma Co., Ltd. 新規なメモリーｃｔｌ誘導増強剤
TWI461436B (zh) 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
AR057253A1 (es) 2005-12-16 2007-11-21 Genentech Inc Anticuerpos anti-ox40l y metodos que los utilizan
US20090155311A1 (en) 2006-01-07 2009-06-18 Med. College Of Georgia Research Institute, Inc. Indoleamine 2,3-dioxygenase pathways in the generation of regulatory t cells
WO2007084559A2 (en) 2006-01-13 2007-07-26 Board Of Regents, The University Of Texas System Methods to treat disease states by influencing the signaling of ox40-receptors and high throughput screening methods for identifying substances therefor
US20110008368A1 (en) 2006-01-13 2011-01-13 Board Of Regents, The University Of Texas System Methods of modulating the ox40 receptor to treat cancer
US20110212086A1 (en) 2006-01-19 2011-09-01 Genzyme Corporation GITR Antibodies For The Treatment of Cancer
GB0603081D0 (en) 2006-02-15 2006-03-29 Dynal Biotech Asa Oslo Method
WO2007111931A2 (en) 2006-03-22 2007-10-04 Imperial Innovations Limited Compositions and methods relating to modulation of immune system components
EP2013348A4 (en) 2006-03-30 2009-09-02 Univ California METHOD AND COMPOSITIONS FOR LOCALIZED SECRETION OF ANTI-CTLA-4 ANTIBODIES
US20090317407A1 (en) 2006-05-02 2009-12-24 Lacelle Michael G Augmentation of immune response to cancer vaccine
MX380352B (es) 2006-06-12 2025-03-12 Aptevo Res & Development Llc Proteinas de union multivalentes monocatenarias con funcion efectora.
WO2008073160A2 (en) 2006-08-17 2008-06-19 The Trustees Of Columbia University In The City Of New York Methods for converting or inducing protective immunity
EP1894941A1 (en) 2006-09-01 2008-03-05 Institut Pasteur Treatment of cervical carcinoma with a recombinant adenylate cyclase carrying HPV antigens
US10106619B2 (en) 2006-10-04 2018-10-23 La Jolla Institute For Allergy And Immunology Virus vaccination and treatment methods with OX40 agonist compositions
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
GB0620894D0 (en) 2006-10-20 2006-11-29 Univ Southampton Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
CA2668693A1 (en) 2006-11-15 2008-05-22 David E. Anderson Therapeutic uses of tim-3 modulators
CA2679399A1 (en) 2007-02-27 2008-09-04 Genetech, Inc. Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases
US20090004213A1 (en) 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
JP2008278814A (ja) 2007-05-11 2008-11-20 Igaku Seibutsugaku Kenkyusho:Kk アゴニスティック抗ヒトｇｉｔｒ抗体による免疫制御の解除とその応用
DK2175884T3 (en) 2007-07-12 2016-09-26 Gitr Inc Combination USING GITR BINDING MOLECULES
CA2699394C (en) 2007-09-17 2020-03-24 The Regents Of The University Of California Internalizing human monoclonal antibodies targeting prostate cancer cells in situ
GB0718167D0 (en) 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target
AU2008307544A1 (en) 2007-10-02 2009-04-09 University Of Rochester Methods and compositions related to synergistic responses to oncogenic mutations
MX2010004910A (es) * 2007-11-08 2010-05-14 Neogenix Oncology Inc Anticuerpos monoclonales recombinantes y antigenos correspondientes para canceres colonico y pancreatico.
EP2242771B1 (en) 2007-12-14 2013-07-17 Bristol-Myers Squibb Company Binding molecules to the human ox40 receptor
EP2240204A1 (en) 2008-02-04 2010-10-20 Medarex, Inc. Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
WO2009141239A1 (en) 2008-05-20 2009-11-26 F. Hoffmann-La Roche Ag A pharmaceutical formulation comprising an antibody against ox40l, uses thereof
RS57132B1 (sr) 2008-07-08 2018-07-31 Incyte Holdings Corp 1,2,5-oksadiazoli kao inhibitori indolamin 2,3-dioksigenaze
US7993640B2 (en) 2008-08-06 2011-08-09 Light Sciences Oncology, Inc. Enhancement of light activated therapy by immune augmentation using anti-CTLA-4 antibody
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
RS54233B1 (sr) 2008-08-25 2015-12-31 Amplimmune Inc. Kompozicije pd-1 antagonista i postupci za njihovu primenu
EP2337795A2 (en) 2008-10-01 2011-06-29 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
US9301785B2 (en) 2008-10-21 2016-04-05 K2M, Inc. Spinal buttress plate
CN102264765B (zh) * 2008-10-28 2016-01-20 盐野义制药株式会社 抗muc1抗体
CA2742969A1 (en) 2008-11-07 2010-05-14 Fabrus Llc Anti-dll4 antibodies and uses thereof
WO2010056898A2 (en) 2008-11-12 2010-05-20 University Of Maryland, Baltimore Rapid expression cloning of human monoclonal antibodies from memory b cells
US8217149B2 (en) 2008-12-09 2012-07-10 Genentech, Inc. Anti-PD-L1 antibodies, compositions and articles of manufacture
PT2398498T (pt) 2009-02-17 2018-12-03 Ucb Biopharma Sprl Moléculas de anticorpo tendo especificidade para ox40 humano
US20120070450A1 (en) 2009-03-24 2012-03-22 Riken Leukemia stem cell markers
CA2757531A1 (en) * 2009-04-07 2010-10-14 Roche Glycart Ag Bispecific anti-erbb-3/anti-c-met antibodies
PL2426148T3 (pl) 2009-04-27 2016-01-29 Kyowa Hakko Kirin Co Ltd Przeciwciało anty-IL-3RA do stosowania w leczeniu nowotworu krwi
JP5808052B2 (ja) 2009-05-29 2015-11-10 中外製薬株式会社 Ｅｇｆファミリーリガンドのアンタゴニストを成分とする医薬組成物
CA2769822C (en) 2009-08-13 2019-02-19 The Johns Hopkins University Methods of modulating immune function
SG178991A1 (en) 2009-09-03 2012-04-27 Schering Corp Anti-gitr antibodies
SG10201501784YA (en) 2009-12-07 2015-05-28 Univ Leland Stanford Junior Methods for enhancing anti-tumor antibody therapy
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
CA2790134A1 (en) 2010-02-16 2011-08-25 Valorisation-Recherche, Limited Partnership Pd-1 modulation and uses thereof for modulating hiv replication
PL2542590T5 (pl) 2010-03-05 2020-08-10 The Johns Hopkins University Kompozycje i sposoby dla ukierunkowanych immunomodulatorowych przeciwciał i białek fuzyjnych
GB201006096D0 (en) 2010-04-13 2010-05-26 Alligator Bioscience Ab Novel compositions and uses thereof
US20110256184A1 (en) 2010-04-14 2011-10-20 Battelle Memorial Institute Non-ordered Mesoporous Silica Structure for Biomolecule Loading and Release
EP2399604A1 (en) 2010-06-25 2011-12-28 F. Hoffmann-La Roche AG Novel antibody formulation
US20120014947A1 (en) 2010-07-16 2012-01-19 The University Of Chicago Methods and compositions to reduce liver damage associated with conditions or therapies that affect the immune system
WO2012012518A2 (en) 2010-07-20 2012-01-26 University Of Miami Inhibition of nonsense mediated decay pathways
PE20180042A1 (es) 2010-08-23 2018-01-09 Univ Texas Anticuerpos anti-ox40 y metodos de uso de los mismos
US20140140986A1 (en) 2010-11-08 2014-05-22 Biovest International, Inc. Materials and methods for directing an immune response to an epitope
US20130323283A1 (en) 2010-12-01 2013-12-05 The Children's Hospital Of Philadelphia Compositions and methods for treating foxp3+ treg related diseases
EP2663580B1 (en) 2011-01-10 2016-12-07 CT Atlantic Ltd. Combination therapy including tumor associated antigen binding antibodies
SI2691417T2 (sl) 2011-03-29 2025-05-30 Roche Glycart Ag FC variante protitelesa
US9409987B2 (en) 2011-04-15 2016-08-09 Compugen Ltd Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
CN107903325B (zh) 2011-05-16 2021-10-29 埃泰美德(香港)有限公司 多特异性fab融合蛋白及其使用方法
DK2714738T3 (en) 2011-05-24 2019-01-28 Zyngenia Inc MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
WO2012163769A1 (en) * 2011-06-03 2012-12-06 Ct Atlantic Ltd. Magea3 binding antibodies
US9132281B2 (en) 2011-06-21 2015-09-15 The Johns Hopkins University Focused radiation for augmenting immune-based therapies against neoplasms
US8841418B2 (en) 2011-07-01 2014-09-23 Cellerant Therapeutics, Inc. Antibodies that specifically bind to TIM3
HRP20180858T1 (hr) 2011-07-11 2018-09-21 Glenmark Pharmaceuticals S.A. Protutijela koja se vežu na ox40 i njihove uporabe
EP3939613A1 (en) 2011-08-11 2022-01-19 ONO Pharmaceutical Co., Ltd. Therapeutic agent for autoimmune diseases comprising pd-1 agonist
JP6038920B2 (ja) 2011-08-23 2016-12-07 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 抗ｏｘ４０抗体およびそれを使用する方法
WO2013039954A1 (en) 2011-09-14 2013-03-21 Sanofi Anti-gitr antibodies
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
AU2013201121A1 (en) 2011-09-20 2013-04-04 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
US9382319B2 (en) 2011-09-26 2016-07-05 Jn Biosciences Llc Hybrid constant regions
WO2013049307A2 (en) 2011-09-30 2013-04-04 University Of Miami Enhanced immune memory development by aptamer targeted mtor inhibition of t cells
BR112014011304B1 (pt) 2011-11-11 2022-03-03 UCB Biopharma SRL Anticorpos de ligação com albumina e fragmentos de ligação dos mesmos, proteína de fusão de anticorpo bi-específico, polinucleotídeo, célula hospedeira, processo de produção de anticorpo ou fragamento do mesmo, formulação farmacêutica e uso
UA112203C2 (uk) 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
US9365496B2 (en) 2011-11-30 2016-06-14 Ludwig Institute For Cancer Research iNKT cell modulators and methods of using the same
GB201120860D0 (en) 2011-12-05 2012-01-18 Cambridge Entpr Ltd Cancer immunotherapy
SI2794658T1 (sl) 2011-12-19 2017-05-31 Synimmune Gmbh Bispecifična molekula protitelesa
AU2013203422A1 (en) 2012-01-06 2013-07-18 Bioalliance C.V. Anti-transferrin receptor antibodies and methods using same
BR112014018331A8 (pt) 2012-01-25 2017-07-11 Univ Texas Biomarcadores e terapias combinadas usando vírus oncolítico e imunomodulação
KR20140126357A (ko) 2012-02-01 2014-10-30 컴퓨젠 엘티디. C1orf32 항체 및 이의 암 치료를 위한 용도
ES2740358T3 (es) 2012-02-06 2020-02-05 Providence Health & Services Oregon Método de supervisión del tratamiento del cáncer con agonistas de OX40
HRP20171585T1 (hr) 2012-02-15 2017-12-01 Novo Nordisk A/S Antitijela koja vezuju i blokiraju aktivirajući receptor eksprimiran na mijeloičnim stanicama 1 (trem-1)
JP2015509717A (ja) 2012-02-22 2015-04-02 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 抗腫瘍活性およびｃａｒ存続性を強化するためのｉｃｏｓベースのｃａｒの使用
JP2015509592A (ja) 2012-02-23 2015-03-30 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ 免疫調節治療剤を用いた処置に対する反応性の予測及びこのような処置の間のアブスコパル効果をモニターする方法
EP2819693A4 (en) 2012-03-02 2015-10-28 Providence Health & Services Oregon ANTICANCER BITHERAPY BASED ON OX40 / IL-2 AGONIST
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
US8993614B2 (en) 2012-03-15 2015-03-31 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides
WO2013142255A2 (en) 2012-03-22 2013-09-26 University Of Miami Multi-specific binding agents
KR101566538B1 (ko) 2012-06-08 2015-11-05 국립암센터 신규한 Ｔｈ17 세포 전환용 에피토프 및 이의 용도
IN2014KN00920A (es) 2012-06-21 2015-10-09 Compugen Ltd
CN103566377A (zh) 2012-07-18 2014-02-12 上海博笛生物科技有限公司 癌症的靶向免疫治疗
AU2013296919A1 (en) 2012-07-30 2015-01-22 Alex Wah Hin Yeung Cancer vaccine comprises tumor cells, an oncolytic virus vector and/or an immune checkpoint modulator
US9540442B2 (en) 2012-08-02 2017-01-10 Jn Biosciences Llc Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece
SMT201900242T1 (it) 2012-12-03 2019-05-10 Bristol Myers Squibb Co Incremento dell'attivita' anti-cancro di proteine di fuzione a fc immunomodulatrici
KR20150134319A (ko) * 2013-01-28 2015-12-01 에베크 인코포레이티드 인간화 항 hmgb1 항체 또는 그의 항원 결합성 단편
WO2015116178A1 (en) * 2014-01-31 2015-08-06 Thomas Jefferson University Fusion proteins for modulating regulatory and effector t cells
WO2014121099A1 (en) 2013-01-31 2014-08-07 Thomas Jefferson University Agonist fusion protein for cd40 ox40 and uses thereof
US9834610B2 (en) 2013-01-31 2017-12-05 Thomas Jefferson University Fusion proteins for modulating regulatory and effector T cells
EP2958571B1 (en) 2013-02-21 2024-04-10 Michele Maio Dna hypomethylating agents for cancer therapy
US10544187B2 (en) 2013-03-15 2020-01-28 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
EP2968985A2 (en) * 2013-03-15 2016-01-20 Amgen, Inc. Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9
ES2699599T3 (es) 2013-03-15 2019-02-11 Abbvie Biotherapeutics Inc Variantes de Fc
EA201591495A1 (ru) 2013-03-18 2016-05-31 Биосерокс Продактс Б.В. Гуманизированные антитела против cd134 (ox40) и применения указанных антител
EP2981286A4 (en) 2013-04-05 2016-08-24 Hoffmann La Roche ANTI-IL-4 ANTIBODIES AND BISPECIFIC ANTIBODIES AND USES THEREOF
TWI487995B (zh) 2013-07-10 2015-06-11 Acer Inc 影像擷取裝置以及其方法
FR3008408B1 (fr) 2013-07-11 2018-03-09 Mc Saf Nouveaux conjugues anticorps-medicament et leur utilisation en therapie
US20160235842A1 (en) 2013-07-15 2016-08-18 The Board Of Trustees Of The Leland Stanford Junior University Medical uses of cd38 agonists
SG11201600310QA (en) 2013-07-16 2016-02-26 Genentech Inc Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
US20150038682A1 (en) 2013-08-02 2015-02-05 Jn Biosciences Llc Antibodies or fusion proteins multimerized via homomultimerizing peptide
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
US10966998B2 (en) 2013-09-05 2021-04-06 The Johns Hopkins University Cancer therapy via a combination of epigenetic modulation and immune modulation
MY176522A (en) 2013-11-04 2020-08-13 Ichnos Sciences SA Production of t cell retargeting hetero-dimeric immunoglobulins
EA201690912A1 (ru) 2013-11-05 2016-10-31 Когнейт Биосервисис, Инк. Комбинации ингибиторов контрольных точек и терапевтических средств для лечения рака
CN106029889A (zh) 2013-11-22 2016-10-12 德那翠丝有限公司 表达免疫细胞刺激受体激动剂的腺病毒
BR112016013963A2 (pt) 2013-12-17 2017-10-10 Genentech Inc terapia de combinação compreendendo agonistas de ligação de ox40 e antagonistas de ligação do eixo de pd-1
JP7060324B2 (ja) 2013-12-20 2022-04-26 ザ・ブロード・インスティテュート・インコーポレイテッド ネオ抗原ワクチンによる併用療法
AU2014372309C1 (en) 2013-12-24 2017-12-14 Janssen Pharmaceutica Nv Anti-VISTA antibodies and fragments
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
US10307472B2 (en) 2014-03-12 2019-06-04 Curevac Ag Combination of vaccination and OX40 agonists
CN114081946A (zh) 2014-03-12 2022-02-25 耶达研究与开发有限公司 降低系统性调节性t细胞水平或活性来治疗cns疾病和损伤
CN107172880B (zh) 2014-03-24 2021-09-28 癌症研究技术有限公司 含有修饰IgG2结构域的引起激动或拮抗特性的修饰抗体及其用途
PE20161571A1 (es) * 2014-03-31 2017-02-07 Genentech Inc Anticuerpos anti-ox40 y metodos de uso
JP6588461B2 (ja) * 2014-03-31 2019-10-09 ジェネンテック， インコーポレイテッド 抗血管新生剤及びｏｘ４０結合アゴニストを含む併用療法
SG10201808746QA (en) 2014-04-03 2018-11-29 Augusta University Research Institute Inc Methods for enhancing the efficacy of a tumor-directed immune response
US20170165230A1 (en) 2014-04-09 2017-06-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
US20150307620A1 (en) * 2014-04-16 2015-10-29 University Of Connecticut Linked immunotherapeutic agonists that costimulate multiple pathways
EP2939690A1 (en) 2014-04-29 2015-11-04 Medizinische Hochschule Hannover Vaccine
BR112016026299A2 (pt) * 2014-05-13 2018-02-20 Chugai Seiyaku Kabushiki Kaisha molécula de ligação ao antígeno redirecionado à célula t para células tendo função de imunossupressão
SG10201912986PA (en) 2014-05-28 2020-02-27 Agenus Inc Anti-gitr antibodies and methods of use thereof
CA2951234C (en) * 2014-06-06 2022-05-31 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
EP3161003A2 (en) 2014-06-27 2017-05-03 Apogenix GmbH Combination of cd95/cd95l inhibition and cancer immunotherapy
US10449227B2 (en) 2014-06-27 2019-10-22 H. Lee Moffitt Cancer Center And Research Institute, Inc. Conjugates for immunotherapy
CN112546231A (zh) 2014-07-09 2021-03-26 博笛生物科技有限公司 用于治疗癌症的联合治疗组合物和联合治疗方法
MX2017000836A (es) 2014-07-18 2017-11-17 Advaxis Inc Composiciones inmunogenicas basadas en listeria para inducir respuestas antitumorales.
WO2016025647A1 (en) 2014-08-12 2016-02-18 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
JO3664B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme أجسام مضادة لـ tigit
CA2960824A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies of alk inhibitors
EP3662903A3 (en) 2014-10-03 2020-10-14 Novartis AG Combination therapies
EP3201232A1 (en) 2014-10-03 2017-08-09 Dana-Farber Cancer Institute, Inc. Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
IL251669B2 (en) 2014-10-10 2023-02-01 Idera Pharmaceuticals Inc Cancer treatment using a tlr9 agonist with checkpoint inhibitors
TW201619200A (zh) 2014-10-10 2016-06-01 麥迪紐有限責任公司 人類化抗－ｏｘ４０抗體及其用途
WO2016059602A2 (en) 2014-10-16 2016-04-21 Glaxo Group Limited Methods of treating cancer and related compositions
AU2015335029B2 (en) 2014-10-24 2021-09-23 Astrazeneca Ab Combination
NZ732211A (en) 2014-10-24 2020-04-24 Calidi Biotherapeutics Inc Combination immunotherapy approach for treatment of cancer
US20180289689A1 (en) 2014-10-27 2018-10-11 Ruprecht-Karls-Universität Heidelberg Use of ccr5 antagonists alone or in combination therapy for the treatment of cancer
EP3215182B1 (en) 2014-11-05 2023-01-04 The Regents of The University of California Combination immunotherapy
KR20170072343A (ko) 2014-11-06 2017-06-26 제넨테크, 인크. Ox40 결합 효능제 및 tigit 억제제를 포함하는 병용 요법
CN106999594B (zh) 2014-11-11 2020-08-18 免疫医疗有限公司 用于治疗瘤形成的治疗组合
LT3221346T (lt) 2014-11-21 2020-11-10 Bristol-Myers Squibb Company Antikūnai, apimantys modifikuotas sunkiosios grandinės pastoviąsias sritis
CN107405398A (zh) 2014-12-05 2017-11-28 伊穆奈克斯特股份有限公司 鉴定vsig8作为推定vista受体及其用以产生vista/vsig8激动剂和拮抗剂的用途
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
US20170340733A1 (en) 2014-12-19 2017-11-30 Novartis Ag Combination therapies
JP2018504894A (ja) 2014-12-19 2018-02-22 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド キメラ抗原受容体およびその使用方法
CN117843799A (zh) 2015-01-08 2024-04-09 生物技术公司 激动性tnf受体结合剂
GB201500319D0 (en) 2015-01-09 2015-02-25 Agency Science Tech & Res Anti-PD-L1 antibodies
AU2016229810A1 (en) 2015-03-11 2017-09-14 Providence Health & Services-Oregon Compositions and methods for enhancing the efficacy of cancer therapy
WO2016154544A1 (en) 2015-03-25 2016-09-29 The Regents Of The University Of Michigan Compositions and methods for delivery of biomacromolecule agents
WO2016168361A1 (en) 2015-04-14 2016-10-20 Polynoma, Llc Polyvalent vaccines and combination therapy for the treatment of melanoma
ES2813580T3 (es) 2015-04-17 2021-03-24 Bristol Myers Squibb Co Composiciones que comprenden una combinación de ipilimumab y nivolumab
CN115109158A (zh) 2015-05-07 2022-09-27 阿吉纳斯公司 抗ox40抗体及其使用方法
CN107849142B (zh) 2015-05-15 2022-04-26 综合医院公司 拮抗性抗肿瘤坏死因子受体超家族抗体
US20160347848A1 (en) 2015-05-28 2016-12-01 Medimmune Limited Therapeutic combinations and methods for treating neoplasia
UY36687A (es) 2015-05-29 2016-11-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Anticuerpos contra ox40 y sus usos
JP7023233B2 (ja) 2015-10-01 2022-02-21 ポテンザ セラピューティックス インコーポレイテッド 抗ｔｉｇｉｔ抗原結合タンパク質と、その使用方法
US20200123265A1 (en) 2015-12-02 2020-04-23 Agenus Inc. Anti-gitr antibodies and methods of use thereof
IL299072A (en) * 2015-12-02 2023-02-01 Memorial Sloan Kettering Cancer Center Antibodies and methods of use thereof
WO2017096276A1 (en) 2015-12-02 2017-06-08 Agenus Inc. Anti-gitr antibodies and methods of use thereof
MA43389A (fr) 2015-12-02 2021-05-12 Agenus Inc Anticorps anti-ox40 et leurs procédés d'utilisation
US20200079862A1 (en) 2015-12-03 2020-03-12 Agenus Inc. Anti-ox40 antibodies and methods of use thereof
LT3429618T (lt) 2016-03-16 2024-05-10 Amal Therapeutics Sa Imuninės sistemos patikros taško moduliatoriaus ir komplekso, apimančio į ląsteles prasiskverbiantį peptidą, krovinį ir tlr peptido agonistą, derinys, skirtas naudoti medicinoje
WO2017186928A1 (en) 2016-04-29 2017-11-02 Curevac Ag Rna encoding an antibody
WO2018089628A1 (en) 2016-11-09 2018-05-17 Agenus Inc. Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof

Also Published As

Publication number Publication date
MA44312A (fr) 2018-10-10
CN108883173B (zh) 2022-09-06
JP2019501883A (ja) 2019-01-24
KR20180083944A (ko) 2018-07-23
US20230399413A1 (en) 2023-12-14
IL299072A (en) 2023-02-01
IL259495B1 (en) 2023-01-01
JP2023105024A (ja) 2023-07-28
IL259495B2 (en) 2023-05-01
TWI717432B (zh) 2021-02-01
TW201734046A (zh) 2017-10-01
US20210171648A1 (en) 2021-06-10
US20230406946A1 (en) 2023-12-21
US20200317797A1 (en) 2020-10-08
EP3383430A4 (en) 2019-12-18
JP7089470B2 (ja) 2022-06-22
SG10201912984WA (en) 2020-03-30
AU2016364889B2 (en) 2024-01-04
WO2017096179A1 (en) 2017-06-08
CA3007233A1 (en) 2017-06-08
CN116063542A (zh) 2023-05-05
CN108883173A (zh) 2018-11-23
SG11201804265XA (en) 2018-06-28
AU2016364889A2 (en) 2018-07-19
TW202134282A (zh) 2021-09-16
EP3383430A1 (en) 2018-10-10
US11447557B2 (en) 2022-09-20
IL259495A (en) 2018-07-31
AU2016364889A1 (en) 2018-06-07
US20200079861A1 (en) 2020-03-12
US10836830B2 (en) 2020-11-17
JP2022079549A (ja) 2022-05-26

Similar Documents

Publication Publication Date Title
MX2018006477A (es) Anticuerpos y metodos de uso de estos.
MY189692A (en) Anti-ox40 antibodies and methods of use thereof
MX2020013062A (es) Anticuerpos anti proteina relacionada con el receptor del factor de necrosis tumoral inducida por glucocorticoides (gitr) y sus metodos de uso.
PH12020552080A1 (en) Dll3-cd3 bispecific antibodies
PH12018500363A1 (en) Bispecific monovalent diabodies that are capable of binding b7-h3 and cd3, and uses thereof
MX2017004311A (es) Anticuerpos del receptor del factor de necrosis tumoral inducido por glucocorticoide (gitr) y metodos de uso de los mismos.
ZA201708265B (en) Tigit-binding agents and uses thereof
MX2018012757A (es) Anticuerpos agonistas que se unen a cd40 humana y usos de los mismos.
NZ707086A (en) Anti-cd40 antibodies and methods of use
MX2015011772A (es) Anticuerpos anti-hepcidina y usos de los mismos.
MA40074A (fr) Composés liant ras multivalents
MX2020004503A (es) Anticuerpos cd3 humanizados o quimericos.
MX2022008523A (es) Compuestos que interactuan con glicanos y metodos de uso.
SG194701A1 (en) Anti-cd40 antibodies and methods of use
EA201401077A1 (ru) Биспецифические антитела к человеческому tweak и человеческому il17 и их применения
MY200162A (en) Anti-gitr antibodies and uses thereof
MX2015017853A (es) Anticuerpos contra el receptor 1 de ldl oxidada tipo lectina de metodos de uso.
MX2015011518A (es) Agentes de enlace de met y usos de los mismos.
MX2014004074A (es) Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2.
PH12015502829A1 (en) Lectin-like oxidized ldl receptor1 antibodies and methods of use
PH12015501360A1 (en) Bmp-6 antibodies
MX2019000963A (es) Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus metodos de uso.
EA201390117A1 (ru) Композиция антител к vegfr-3
MA40363A (fr) Agents de liaison de rspo1 et leurs utilisations
HK1232467A1 (en) Anti-gitr antibodies and methods of use thereof